Alteplase

Alteplase
Clinical data
Trade namesActivase, Actilyse, Cathflo Activase, others
Other namest-PA, rt-PA
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B1
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC2569H3928N746O781S40
Molar mass59042.52 g·mol−1
  (verify)

Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure, and blocked central venous catheter.[5] Alteplase is given by injection into a vein or artery.[5] Alteplase is the same as the normal human plasminogen activator produced in vascular endothelial cells[6] and is synthesized via recombinant DNA technology in Chinese hamster ovary cells (CHO). Alteplase causes the breakdown of a clot by inducing fibrinolysis.[7]

It is on the World Health Organization's List of Essential Medicines.[8]

Blood flow obstructed by coagulated blood that could potentially be reversed with alteplase.
  1. ^ Australian Public Assessment Report for Alteplase (AusPAR) (PDF). Therapeutic Goods Administration (TGA) (Report). February 2011.
  2. ^ Cite error: The named reference Activase FDA label was invoked but never defined (see the help page).
  3. ^ Cite error: The named reference Cathflo Activase FDA label was invoked but never defined (see the help page).
  4. ^ "Actilyse". European Medicines Agency. 17 September 2018. Archived from the original on 17 November 2020. Retrieved 14 November 2020.
  5. ^ a b "Alteplase Monograph for Professionals". Drugs.com. Archived from the original on 27 August 2020. Retrieved 11 November 2019.
  6. ^ Baskin JL, Pui CH, Reiss U, Wilimas JA, Metzger ML, Ribeiro RC, et al. (July 2009). "Management of occlusion and thrombosis associated with long-term indwelling central venous catheters". Lancet. 374 (9684): 159–69. doi:10.1016/S0140-6736(09)60220-8. PMC 2814365. PMID 19595350.
  7. ^ Cite error: The named reference :6 was invoked but never defined (see the help page).
  8. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.